发明授权
- 专利标题： Fused Tricyclic Compounds as novel mTOR inhibitors
- 专利标题（中）： 融合的三环化合物作为新的mTOR抑制剂
-
申请号： US13379685申请日： 2010-06-30
-
公开(公告)号： US08609675B2公开(公告)日： 2013-12-17
- 发明人: Cliff C. Cheng , Hongbo Zeng , Gerald W. Shipps, Jr. , Yongqi Deng , Zhaoyang Meng , Lianyun Zhao , Yang Nan , Binyuan Sun , Duan Liu , Panduranga A. Reddy , M. Arshad Siddiqui
- 申请人： Cliff C. Cheng , Hongbo Zeng , Gerald W. Shipps, Jr. , Yongqi Deng , Zhaoyang Meng , Lianyun Zhao , Yang Nan , Binyuan Sun , Duan Liu , Panduranga A. Reddy , M. Arshad Siddiqui
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 代理商 Li Su; Laura M. Ginkel
- 国际申请： PCT/US2010/040604 WO 20100630
- 国际公布： WO2011/002887 WO 20110106
- 主分类号： A01N43/54
- IPC分类号： A01N43/54 ; C07D491/00
摘要：
The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.
公开/授权文献
- US20120178744A1 FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS 公开/授权日：2012-07-12